NCT02974686View on ClinicalTrials.gov

Conversion From MPA to Zortress (Everolimus) for GI Toxicity Post-renal Transplantation

PHASE4TerminatedINTERVENTIONAL

Enrollment

1

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

September 30, 2019

Study Completion Date

September 30, 2019

Conditions

Kidney Transplant RejectionGastrointestinal Disorder, Functional

Interventions

DRUG

Everolimus

DRUG

Mycophenolic Acid

Trial Locations (1)

63110

Washington University, St Louis

Sponsors

Collaborators (1)

Novartis Pharmaceuticals

All Listed Sponsors

collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

Washington University School of Medicine

OTHER